News & Updates
Filter by Specialty:
Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females
In a pooled analyses of data from the EAGLE*-2 and EAGLE-3 studies, the investigational, first-in-class, oral, triazaacenaphthylene bactericidal antibiotic gepotidacin showed consistent therapeutic efficacy across key patient subgroups and had an acceptable safety profile in female adults and adolescents with uncomplicated urinary tract infections (uUTI) compared with nitrofurantoin.
Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females
25 Oct 2023How safe is long-term bimekizumab in plaque psoriasis patients?
Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.
How safe is long-term bimekizumab in plaque psoriasis patients?
24 Oct 2023Risankizumab proven safe, effective in bio-naïve psoriasis patients
Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.
Risankizumab proven safe, effective in bio-naïve psoriasis patients
24 Oct 2023Oral health checks integral to diabetes management
A population-based study suggests that the incidence of periodontitis co-occurs with various other diabetes-related complications, underpinning the importance of oral health checks in diabetes management.